Shopping Cart
Remove All
Your shopping cart is currently empty
UZH1 is a racemate of UZH1a and UZH1b. UZH1a is a potent and selective METTL3 inhibitor with an IC50 of 280 nM, while UZH1b (IC50=28 μM) is essentially inactive. UZH1 can be used for epitranscriptomic modulation of cellular processes, has antitumor activity, and serves as a chemical probe for studying METTL3[1].

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 5 mg | $332 | Inquiry | Inquiry | |
| 10 mg | $564 | Inquiry | Inquiry | |
| 25 mg | $1,120 | Inquiry | Inquiry | |
| 50 mg | $1,820 | Inquiry | Inquiry | |
| 100 mg | $2,820 | Inquiry | Inquiry |
| Description | UZH1 is a racemate of UZH1a and UZH1b. UZH1a is a potent and selective METTL3 inhibitor with an IC50 of 280 nM, while UZH1b (IC50=28 μM) is essentially inactive. UZH1 can be used for epitranscriptomic modulation of cellular processes, has antitumor activity, and serves as a chemical probe for studying METTL3[1]. |
| In vitro | UZH1a (2.5-160 μM; 72 h) inhibits the growth of MOLM-13, HEK293T, and U2Os cells, with IC50s of 11 μM, 67 μM, and 87 μM, respectively. UZH1b (2.5-160 μM; 72 h) inhibits the growth of the same cells, with IC50s of 78 μM, 79 μM, and 93 μM, respectively[1]. UZH1a (2.5-100 μM; 16 h) reduces m6A methylation levels in mRNA from cells dose-dependently (IC50=4.6 μM), whereas UZH1b is less active at concentrations up to 100 μM in MOLM-13 cells. UZH1a (40 μM; 16 h) reduces m6A methylation levels in mRNA from MOLM-13, HEK293T, and U2Os cells. Furthermore, UZH1a (20 μM; 16 h) increases apoptosis and induces cell cycle arrest in MOLM-13 cells[1]. |
| Synonyms | UZH1 |
| Molecular Weight | 558.71 |
| Formula | C32H42N6O3 |
| Cas No. | 2925713-02-4 |
| Smiles | C(NC(=O)C1=C(O)C=C(CN2CCC(C)(C)CC2)C=C1)C3(O)CN(CCC3)C=4C=C(NCC5=CC=CC=C5)N=CN4 |
| Relative Density. | no data available |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 125 mg/mL (223.73 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+40% PEG300+5% Tween-80+45% Saline: 5 mg/mL (8.95 mM), Sonication is recommeded. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
| ||||||||||||||||||||||||||||||||||||
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.